Author

Andres Yarur 1

1 Medical College of Wisconsin,Milwaukee,United States

Clinical Effectiveness of First-Line Anti-TNF Therapies and Second-Line Anti-TNF Therapy Post-Vedolizumab Discontinuation in Patients with Ulcerative Colitis or Crohn's Disease

Brian Bressler, Andres Yarur, Uri Kopylov, Marielle Bassel, Neil Brett, Trevor Lissoos, claudia lopez, Athanasios Natsios, Sumit Saha, Christina Kifnidi, Dirk Demuth, Haridarshan Patel, Gerassimos J. Mantzaris

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Brian G. Feagan, Laurent Peyrin-Biroulet, William J. Sandborn, Geert R. D'Haens, Julian Panés, Andres Yarur, Douglas C. Wolf, Timothy Ritter, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J. Rabbat, Michael Chiorean, Filip Baert, Bruce E. Sands, Marla C. Dubinsky, Severine Vermeire, Martina Goets

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

William J. Sandborn, Severine Vermeire, Laurent Peyrin-Biroulet, Marla C. Dubinsky, Julian Panés, Andres Yarur, Timothy Ritter, Filip Baert, Stefan Schreiber, Sheldon Sloan, Fabio Cataldi, Kevin Shan, Christopher J. Rabbat, Michael Chiorean, Douglas C. Wolf, Bruce E. Sands, Geert R. D'Haens, Silvio Danese, Martina Goetsch

REAL-WORLD EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A POOLED MULTICENTRE OBSERVATIONAL COHORT ANALYSIS OF CLINICAL AND MODELED PHARMACOLOGICAL DATA

Niels Vande Casteele, William Sandborn, Brian G. Feagan, Severine Vermeire, Parambir Dulai, Julian Panés, Andres Yarur, Xavier Roblin, Shomron Ben-Horin, Iris Dotan, Mark Osterman, Dirk Lindner, Christian Agboton, Maria Rosario, Teresa Osborn

Real-world Safety of Vedolizumab and Anti-TNF Therapies in Biologic-Naïve Ulcerative Colitis and Crohn's Disease Patients: Results from the EVOLVE study

Andres Yarur, Gerassimos J. Mantzaris, Uri Kopylov, Marielle Bassel, Neil Brett, Trevor Lissoos, claudia lopez, Athanasios Natsios, Christina Kifnidi, Sumit Saha, Dirk Demuth, Haridarshan Patel, Brian Bressler

SIMPLIFIED RULES TO IDENTIFY BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE WITH HIGHER LIKELIHOOD OF CLINICAL REMISSION WHEN INITIATING VEDOLIZUMAB VERSUS ANTI-TNF THERAPIES: ANALYSIS OF EVOLVE STUDY DATA

Gerassimos J. Mantzaris, Andres Yarur, Annie Guerin, Pravin Kamble, Michelle Luo, Song Wang, Ha Nguyen, Emma Billmyer, Brian Bressler, Shashi Adsul

THE INCREMENTAL RATE OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE COMPARED TO PATIENTS WITHOUT IMMUNE-MEDIATED DISEASES

Andres Yarur, Juliana Setyawan, Fan Mu, Miriam Zichlin, Catherine Fernan, Emma Billmyer, Nathaniel Downes, Hongbo Yang, Nassir Azimi

THE INCREMENTAL RATE OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE COMPARED TO PATIENTS WITHOUT IMMUNE-MEDIATED DISEASES

Andres Yarur

Item 1 - 8 / 8
1